Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis

The current standard of care for resected early-stage triple negative breast cancer (TNBC) patients who did not receive systemic preoperative therapy is adjuvant anthracycline- and taxane-based chemotherapy (CT). A network meta-analysis (NMA) of randomized controlled trials (phase III) enrolling pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrelli, Fausto, Bertaglia, Valentina, Parati, Maria Chiara, Borgonovo, Karen, De Silva, Pushpamali, Luciani, Andrea, Novello, Silvia, Scartozzi, Mario, Emens, Leisha A., Solinas, Cinzia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792383/
https://www.ncbi.nlm.nih.gov/pubmed/36549170
http://dx.doi.org/10.1016/j.breast.2022.12.004
_version_ 1784859624174780416
author Petrelli, Fausto
Bertaglia, Valentina
Parati, Maria Chiara
Borgonovo, Karen
De Silva, Pushpamali
Luciani, Andrea
Novello, Silvia
Scartozzi, Mario
Emens, Leisha A.
Solinas, Cinzia
author_facet Petrelli, Fausto
Bertaglia, Valentina
Parati, Maria Chiara
Borgonovo, Karen
De Silva, Pushpamali
Luciani, Andrea
Novello, Silvia
Scartozzi, Mario
Emens, Leisha A.
Solinas, Cinzia
author_sort Petrelli, Fausto
collection PubMed
description The current standard of care for resected early-stage triple negative breast cancer (TNBC) patients who did not receive systemic preoperative therapy is adjuvant anthracycline- and taxane-based chemotherapy (CT). A network meta-analysis (NMA) of randomized controlled trials (phase III) enrolling patients with resected stage I-III TNBC comparing adjuvant regimens was performed. Overall survival (OS) and disease-free survival (DFS) data were extracted. A total of 27 phase III clinical trials were selected including 15,242 TNBC patients. This NMA showed an OS benefit from the incorporation of capecitabine into classic anthracycline/taxane-based combinations compared to anthracyclines with or without taxanes alone.
format Online
Article
Text
id pubmed-9792383
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97923832022-12-28 Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis Petrelli, Fausto Bertaglia, Valentina Parati, Maria Chiara Borgonovo, Karen De Silva, Pushpamali Luciani, Andrea Novello, Silvia Scartozzi, Mario Emens, Leisha A. Solinas, Cinzia Breast Short Communication The current standard of care for resected early-stage triple negative breast cancer (TNBC) patients who did not receive systemic preoperative therapy is adjuvant anthracycline- and taxane-based chemotherapy (CT). A network meta-analysis (NMA) of randomized controlled trials (phase III) enrolling patients with resected stage I-III TNBC comparing adjuvant regimens was performed. Overall survival (OS) and disease-free survival (DFS) data were extracted. A total of 27 phase III clinical trials were selected including 15,242 TNBC patients. This NMA showed an OS benefit from the incorporation of capecitabine into classic anthracycline/taxane-based combinations compared to anthracyclines with or without taxanes alone. Elsevier 2022-12-15 /pmc/articles/PMC9792383/ /pubmed/36549170 http://dx.doi.org/10.1016/j.breast.2022.12.004 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Short Communication
Petrelli, Fausto
Bertaglia, Valentina
Parati, Maria Chiara
Borgonovo, Karen
De Silva, Pushpamali
Luciani, Andrea
Novello, Silvia
Scartozzi, Mario
Emens, Leisha A.
Solinas, Cinzia
Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
title Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
title_full Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
title_fullStr Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
title_full_unstemmed Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
title_short Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
title_sort adjuvant chemotherapy for resected triple negative breast cancer patients: a network meta-analysis
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792383/
https://www.ncbi.nlm.nih.gov/pubmed/36549170
http://dx.doi.org/10.1016/j.breast.2022.12.004
work_keys_str_mv AT petrellifausto adjuvantchemotherapyforresectedtriplenegativebreastcancerpatientsanetworkmetaanalysis
AT bertagliavalentina adjuvantchemotherapyforresectedtriplenegativebreastcancerpatientsanetworkmetaanalysis
AT paratimariachiara adjuvantchemotherapyforresectedtriplenegativebreastcancerpatientsanetworkmetaanalysis
AT borgonovokaren adjuvantchemotherapyforresectedtriplenegativebreastcancerpatientsanetworkmetaanalysis
AT desilvapushpamali adjuvantchemotherapyforresectedtriplenegativebreastcancerpatientsanetworkmetaanalysis
AT lucianiandrea adjuvantchemotherapyforresectedtriplenegativebreastcancerpatientsanetworkmetaanalysis
AT novellosilvia adjuvantchemotherapyforresectedtriplenegativebreastcancerpatientsanetworkmetaanalysis
AT scartozzimario adjuvantchemotherapyforresectedtriplenegativebreastcancerpatientsanetworkmetaanalysis
AT emensleishaa adjuvantchemotherapyforresectedtriplenegativebreastcancerpatientsanetworkmetaanalysis
AT solinascinzia adjuvantchemotherapyforresectedtriplenegativebreastcancerpatientsanetworkmetaanalysis

Ejemplares similares